Latest Cholangiocarcinoma Stories
Agreement represents continued movement forward in the development of a potential new treatment for rare cancers TORONTO and BANNOCKBURN, Ill., Jan.
A team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute (Romania) and Koen Kaen University (Thailand), have made a seminal breakthrough in understanding the molecular basis of bile duct cancer or cholangiocarcinoma, a rare but highly lethal form of liver cancer.
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone.
New data from two clinical trials presented today at the International Liver Congress™ 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests.
Investigators at the University of Texas MD Anderson Cancer Center, Houston, have reported on a new approach to treating previously inoperable complex pancreatic adenocarcinoma that has significantly increased long-term survival for some patients.
Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer.
A method of molecular imaging that pinpoints hormonally active tissues in the body could change the course of treatment for a remarkable number of neuroendocrine cancer patients.
A novel pancreatic cancer vaccine shows promise in improving survival when added to standard treatment.
The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node negative non-small cell lung cancer.
The Chinese liver fluke (Clonorchis sinensis) is a species of parasitic worm that is classified within the Platyhelminthes phylum. It can be found in Southeast Asia, Taiwan, Japan, and China and is present in nearly 30,000,000 humans today. It is thought to be one of the world’s most pervading parasites. The Chinese liver fluke requires two intermediate, or secondary, hosts and one definitive, or main, host to successfully complete its lifecycle. The first intermediate host is typically...
- totally perplexed and mixed up.